These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 843215)

  • 1. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
    Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
    Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
    Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Deutschmann KE; Peter HH; Schultheis W; Deicher H
    Tumori; 1977; 63(3):303-7. PubMed ID: 898298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
    Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of administering B.C.G. to patients with melanoma.
    Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
    Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract]   [Full Text] [Related]  

  • 20. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.